# Sangel Capital

> Sangel Capital is a VC fund in Shenzhen backing Health Care and Biotechnology. See 25 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Shenzhen, China
- Total investments: 25
- Last investment: Mar 2024
- Lead investor: 12%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sangel-capital/about/
- Website: http://www.sage-angel.com/en/Default.aspx

Sangel Capital is a biomedical venture capital firm

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 13 | 52% |
| Biotechnology | 11 | 44% |
| Medical | 10 | 40% |
| Pharmaceutical | 6 | 24% |
| Biopharma | 4 | 16% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 10 | 40% |
| Series B | 7 | 28% |
| Series D | 2 | 8% |
| Seed | 1 | 4% |
| Angel | 1 | 4% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 13 | 52% |
| United States | 4 | 16% |
| Canada | 1 | 4% |
| Cayman Islands | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Proviva Therapeutics, Inc | Prodrug design platform for cytokines and other fusion proteins | $18M | Series A | Mar 05, 2024 |  |
| BioTroy Therapeutics | BioTroy Therapeutics is engaged in tumor immunity and is used for multi-omics tumor analysis, receptor-ligand discovery, research on target signal transduction pathways, antibody discovery and engineering, drug efficacy and large animal translational medicine, biomarkers, and precision medicine. | $14.4M | Seed | Mar 07, 2023 |  |
| Yiyao Technology | Yiyao Technology is a health care company. | $1.6M | Angel | Mar 15, 2022 |  |
| SparX Group | SparX Group is a biotech firm that develops innovative anticancer biologics through bispecific antibodies and drug conjugates. | $30M | Series B | Dec 31, 2021 |  |
| Aucta Pharmaceuticals China | Aucta Pharmaceuticals China is a provider of a drug development platform intended to improve drug delivery. | $15.6M | Series A | Nov 04, 2021 |  |
| Joyo Pharma | Joyo Pharma focuses on the research and development of drugs for the treatment of tumors, autoimmunity, metabolism, and infectious diseases. | $46.2M | Series B | Jul 28, 2021 |  |
| Aucta Pharmaceuticals China | Aucta Pharmaceuticals China is a provider of a drug development platform intended to improve drug delivery. |  | Series A | Mar 10, 2021 |  |
| Ascentawits | Ascentawits focuses on developing small molecule targeted conjugated anti-tumor drugs. The company utilizes specific tumor micro-environments to carry out independent innovative drug designs and screening for the development of new anti-tumor drugs. | $15.5M | Series A | Feb 11, 2021 |  |
| LongBio Pharma | LongBio Pharma is a biotech company that treats patients with an emphasis on complement and allergy diseases. | $15.5M | Series A | Jan 04, 2021 |  |
| Denovo Biopharma | Denovo Biopharma is a privately held biotech company providing a novel biomarker solution to personalize drug development. The core technology is the industry's first platform and algorithm to perform de novo genomic biomarker discovery retrospectively using archived clinical samples. This technology is especially useful for late stageclinical drugs that have completed trials with unsatisfactory efficacy. By identifying biomarkers correlated to patients' responsiveness to drug candidates retrospectively, our technology enables biotech and pharmaceutical companies to design new clinical trials in a targeted patient population to achieve significant efficacy and/or less adverse effects. Our platform can be broadly applied to biomarker discovery in many therapeutic areas, such as oncology, metabolic, cardiology, immunology and neurology. | $42.5M | Series D | Dec 10, 2020 |  |

10 of 25 investments shown.

## Co-investors
- [SDIC Venture Capital](https://shizune.co/investors/profile/sdic-venture-capital) — VC Fund, 4 deals together
- [Cowin Venture](https://shizune.co/investors/profile/cowin-venture) — VC Fund, 3 deals together
- [Fang Fund Partners](https://shizune.co/investors/profile/fang-fund-partners) — VC Fund, 3 deals together
- Purity Star — VC Fund, 3 deals together
- Dahua Investment — VC Fund, 2 deals together
- [Furong Capital](https://shizune.co/investors/profile/furong-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Sangel Capital invest in?

Sangel Capital invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series B stage. Most of the 25 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Sangel Capital last invest?

The most recent investment recorded for Sangel Capital closed in Mar 2024. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co